London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What’s not to like
Agree Merchant Banker that’s why it will be taken out or JV ....production won’t be able to satisfy demand imo
Elisa capacity = 1m per week = 52m per year.
Global population = 7.8bn
Assume the market for antibody tests is the whole population - it wont reach 100% but will be offset with repeat testing
We only need to capture 0.5% of the total market in order to reach 100% utilisation. Orders will not be a problem. The test is one of the better performing tests, cheaper and therefore more accessible to all markets and unlike the Roche test doesn't require specific equipment to analyse. The biggest problem will be satisfying demand.
You have to ask the question Why wouldn’t they order? This is their only option - who else can they buy from? The logistics to open up such a highly populated country are mind bending, this gold standard test will be their saviour. Anything else is complete bull and doubt being cast is an attempt to sway the situation and deflection about OO being taken up is a complete red herring designed to sow seeds by shorters. This is the first stop on the road to riches. £1 shortly is absolutely nailed on here imho
IMHO DYOR GLA
One order from India, that’s all it will take. No one knows the potential sales and what countries want to actually do.
So India could order full Elisa capacity out of Ely in one go, one order as their country is so big and they will prefer British than Chinese everyday.
The other huge positive is once one country approves others tend to have more confidence and follow suit
Then have access into government for future tests which supports antigen, lateral flow.
In India lateral, POC tests will win every time based on physical circumstances and lack of power and distribution
Denn - how many times...we need ORDERS. Market sentiment is not there for waffle. Same over at all Covid stocks. Market needs orders/numbers and revenue now. The talking has been done for months. We need to see sold orders now. Then the SP with rise and the MC will grow. Just because they have been approved in India doesn't meant they'll sell 1 test there. Now we all know they will sell millions so that is why its a great time to invest now. The MC doesn't reflect the future revenue and untill we get orders it will stay there.
And this only moves a few %. Taking **** or what? £60m mrkt cap. This should be a £1 a share at the very least. Must be some games going on here